The study design of this trial is open-label, randomized, multi-center, parallel-group study.
Drug: Glimepiride/ Metformin
Drug: Glimepiride/ Metformin
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT01444248
Ages eligible for Study
18 Years to 75 Years
Genders eligible for Study
Accepts Healthy Volunteers
Patients aged between 18 ~ 75 years at screening
Patients who have been diagnosed with type 2 DM for at least 3 months
Patients who were treated with a stable dose with combination therapy of glimepiride 4mg or more and metformin 1000mg or more which can switch to Amaryl M 2/500mg bid or Amaryl Mex 2/500mg 2T od regimen.
HbA1c ≤ 9 % at randomization
BMI ≤ 40 kg/m2 at randomization
Patients who would give the informed consent
Patients who can perform SMBG and record the data on the patient's diary
Patients who can understand and use MEMS properly
Patients with the medical history of acute metabolic complications such as diabetic ketoacidosis, hyperosmolar nonketotic coma within 3 months prior to the study participation
Patients who are under insulin therapy at randomization
Patients who received systemic corticosteroid agent within 4 weeks prior to the study participation
Patients with acute, severe cardiovascular disease (e.g., heart failure, myocardial infarction, stroke, etc).
Pregnant or lactating females
history of drug or alcohol abuse
Patients with known hypersensitivity to the ingredient of the study drug or drugs in sulfonylurea, sulfonamide, biguanide class
Patients with an experience of participating in other clinical trial within 3 months prior to the study participation
Clinically significant laboratory abnormality on screening labs or any medical condition that would affect the completion or outcome of the study based on investigator's decision
Patients with serum creatinine level > 1.5 mg/dl in male and > 1.4 mg/dl in female
Patients with ALT or AST > 3x ULN
Any conditions requiring help of others with drug administration (e.g. manual disability, serious visual defect, etc.)
All locations for NCT01444248
Korea, Republic of (1)
Seoul, Korea, Republic of
View full eligibility
Tris trial is registered with FDA with number: NCT01444248. The sponsor of the trial is Handok Inc. and it is looking for 168 volunteers for the current phase.
Official trial title: A Multi-center, Open, Randomized, Parallel-group Study to Compare the Compliance of Patients Treated With Once-daily (od) or Twice-daily (Bid) Glimepiride and Metformin Fixed Combination Therapy
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.